Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,466,483
  • Shares Outstanding, K 92,094
  • Annual Sales, $ 451,240 K
  • Annual Income, $ 21,110 K
  • 60-Month Beta 1.24
  • Price/Sales 23.22
  • Price/Cash Flow 226.90
  • Price/Book 18.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.72
  • Number of Estimates 8
  • High Estimate 0.92
  • Low Estimate 0.58
  • Prior Year 0.19
  • Growth Rate Est. (year over year) +278.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
106.15 +6.08%
on 12/11/19
119.65 -5.89%
on 12/04/19
+1.75 (+1.58%)
since 11/11/19
3-Month
84.68 +32.98%
on 10/08/19
119.65 -5.89%
on 12/04/19
+17.19 (+18.02%)
since 09/11/19
52-Week
64.72 +73.98%
on 12/12/18
119.65 -5.89%
on 12/04/19
+26.84 (+31.30%)
since 12/11/18

Most Recent Stories

More News
Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

Overview of Clinical Stage XEN901 and Related Patient Survey to be Presented in the "Genetic Epilepsies - Updates in the Science and Diagnosis" Exhibit in Room 318-319 on Sunday, December 8

XENE : 13.36 (-8.81%)
NBIX : 113.25 (-0.35%)
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced a license and collaboration agreement to develop first-in-class treatments for epilepsy.

NBIX : 113.25 (-0.35%)
XENE : 13.36 (-8.81%)
Uptrend Call Working As Neurocrine Biosc Stock Rises 26.4% (NBIX)

SmarTrend identified an Uptrend for Neurocrine Biosc (NASDAQ:NBIX) on October 16th, 2019 at $93.16. In approximately 1 month, Neurocrine Biosc has returned 26.40% as of today's recent price of $117.75....

NBIX : 113.25 (-0.35%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 54.84 (-0.47%)
IBB : 119.48 (-0.52%)
XBI : 94.27 (-1.32%)
VRTX : 220.00 (-0.12%)
BIIB : 292.23 (-1.67%)
NBIX : 113.25 (-0.35%)
Neurocrine Biosciences to Present at Evercore ISI 2nd Annual HealthCONx Conference

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Evercore ISI 2nd Annual HealthCONx Conference at 8:45 a.m. Eastern Time on Tuesday, Dec. 3, 2019, in Boston. Kevin Gorman, Chief Executive...

NBIX : 113.25 (-0.35%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Clovis Oncology (CLVS , ESPR , NBIX , RGEN , AGIO )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CLVS : 11.72 (-3.14%)
ESPR : 50.13 (-0.32%)
NBIX : 113.25 (-0.35%)
Neurocrine Biosc Rises 1.99% on Heavy Volume: Watch For Potential Pullback

Neurocrine Biosc (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $113.16 to a high of $115.99. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high...

NBIX : 113.25 (-0.35%)
Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive Dyskinesia

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the Journal of Clinical Psychopharmacology1 published long-term data from the KINECT 4 Phase III, open-label study of INGREZZA® (valbenazine)...

NBIX : 113.25 (-0.35%)
Watch for Neurocrine Biosc to Potentially Pullback After Gaining 23.72% Yesterday

Neurocrine Biosc (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $110.51 to a high of $113.07. Yesterday, the shares gained 23.7%, which took the trading range above the 3-day high...

NBIX : 113.25 (-0.35%)
20.0% Return Seen to Date on SmarTrend Neurocrine Biosc Call (NBIX)

SmarTrend identified an Uptrend for Neurocrine Biosc (NASDAQ:NBIX) on October 16th, 2019 at $93.16. In approximately 4 weeks, Neurocrine Biosc has returned 20.03% as of today's recent price of $111.82....

NBIX : 113.25 (-0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NBIX with:

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

2nd Resistance Point 115.44
1st Resistance Point 114.55
Last Price 113.25
1st Support Level 112.92
2nd Support Level 112.18

See More

52-Week High 119.65
Last Price 113.25
Fibonacci 61.8% 98.67
Fibonacci 50% 92.18
Fibonacci 38.2% 85.70
52-Week Low 64.72

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar